Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
08
According to recent research from Vienna, Austria, Sporadic colorectal cancer is a disease of advancing age and the percentage of the population which reaches an advanced age is strongly, increasing. Multiple factors are responsible for the etiology of this cancer since the colorectal mucosa is directly influenced by, nutrients reaching the colonic lumen and impacting on mucosal cells.
Genetic variability in drug-metabolizing enzymes and signaling pathways affects chemotherapy- related toxicity and treatment outcome in cancer. in breast and colorectal. cancer, polymorphisms in metabolic enzymes involved in tamoxifen and irinotecan therapies has led the U.S. Food and Drug Administration to address genetic factors relevant to patient consideration of treatment with these compounds, investigators in the United States report.
01
Although overall incidence and death rates from colorectal cancer are decreasing, the gap in death rates between African-Americans and Caucasians has widened. Colorectal cancer is the third most common cancer among both African- American men and women, however, it is preventable and some screening programs within the African-American community are working to reduce the incidence of this disease.
According to recent research published in the journal Cancer Research, Identification of the active component and mechanisms of action of traditional medicines is highly desirable. We investigated whether zerumbone, a sesquiterpene from tropical ginger, can enhance the anticancer effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Research findings, 'Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study,' are discussed in a new report. The authors developed a comprehensive model of colon cancer incidence that allows for nonproportional hazards and accounts for the temporal nature of risk factors. They estimated relative risk based on cumulative incidence of colon cancer by age 70 years, researchers in the United States report.
29
MabCure, Inc., a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC).
Whispering Oaks International, Inc., d/b/a Biocurex, announced today that it is making two presentations at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) being held this week in Amsterdam, The Netherlands. BioCurex's presentations address its RECAF cancer market test in combination with other currently used cancer markers: CA-125 for ovarian cancer and CEA for colorectal cancer.
24
Investing in some colorectal cancer screening programs could cut future, more expensive treatment costs in half, according to a new study published online September 24 in theJournal of the National Cancer Institute. The only screening program found not to be cost-saving was colonoscopy.
Neogenix Oncology, Inc. (Neogenix) announced that NPC-1C, the company's first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial.
Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced that its ColoMarker assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre- clinical trials.
We care about your feedback. Let us know how we can improve your CancerCompass experience.